Transcat (TRNS) Expected to Release Quarterly Earnings on Tuesday

Transcat (NASDAQ:TRNS) is projected to release its Q2 2027 results after the market closes on Tuesday, November 3rd. Analysts expect Transcat to post earnings of $0.4475 per share and revenue of $92.43 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2027 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Transcat (NASDAQ:TRNS) last announced its quarterly earnings results on Tuesday, August 4th. The scientific and technical instruments company reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.13. Transcat had a net margin of 0.99% and a return on equity of 5.56%. The firm had revenue of $92.95 million during the quarter, compared to analysts’ expectations of $86.55 million. On average, analysts expect Transcat to post $1.74 EPS for the current fiscal year and $1.92 EPS for the next fiscal year.

Transcat Trading Up 1.7%

NASDAQ:TRNS opened at $83.33 on Tuesday. The business’s 50-day moving average is $86.46 and its two-hundred day moving average is $81.10. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.49 and a quick ratio of 2.11. Transcat has a 12 month low of $50.23 and a 12 month high of $100.00. The firm has a market capitalization of $782.47 million, a PE ratio of 225.22 and a beta of 0.66.

Insiders Place Their Bets

In other news, Director Craig Cairns acquired 1,050 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was bought at an average cost of $93.97 per share, with a total value of $98,668.50. Following the transaction, the director directly owned 1,480 shares in the company, valued at approximately $139,075.60. This represents a 244.19% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Christopher P. Gillette sold 504 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $94.23, for a total value of $47,491.92. Following the sale, the director owned 200 shares of the company’s stock, valued at $18,846. This represents a 71.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 1.80% of the company’s stock.

Analysts Set New Price Targets

TRNS has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Transcat in a research note on Tuesday, August 25th. Northland Securities raised Transcat from a “market perform” rating to an “outperform” rating and set a $95.00 price target on the stock in a research report on Wednesday, October 21st. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Transcat presently has an average rating of “Hold” and a consensus target price of $95.00.

Transcat Company Profile

Transcat, Inc (NASDAQ: TRNS) provides calibration, compliance, and measurement services for organizations that rely on accurate test and measurement equipment. The company supports customers in regulated industries, including life sciences, aerospace and defense, energy, manufacturing, and other industrial markets.

Its service offerings include laboratory and onsite calibration, repair, validation, and asset-management services. Transcat calibrates a broad range of equipment used to measure temperature, pressure, electrical and electronic properties, radio frequency signals, dimensional characteristics, and other technical parameters.